All the news Showing 10 of 46 articles from: Access to medicines & diagnosticsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources How generic direct-acting antivirals are changing the landscape for hepatitis C treatment Keith Alcorn / 19 April 2016 The arrival of generic versions of direct-acting antivirals is transforming the global hepatitis C treatment landscape and highlighting the overlooked importance of the cost of monitoring technologies, delegates at the 2016 International Liver ... Low-cost generic hepatitis C drugs match branded products in viral responses Keith Alcorn / 16 April 2016 Generic versions of direct-acting antivirals purchased from China and India by people unable to obtain treatment in their own countries were just as effective and safe as the branded products, a study ... $300 hepatitis C combination to enter clinical trials Keith Alcorn / 13 April 2016 The Drugs for Neglected Diseases Initiative (DNDI) is launching clinical trials in Thailand and Malaysia to test a combination of sofosbuvir and ravidasvir, an NS5A inhibitor, in at least 800 people with ... Sofosbuvir/daclatasvir combination could be produced for $200 per cure Keith Alcorn / 14 December 2015 Month-by-month tracking of the prices paid in India for the chemicals used to make hepatitis C direct-acting antivirals shows that it is now possible to make and sell a combination of drugs ... Almost half of US Medicaid recipients denied funding for hepatitis C treatment, 4-state study shows Keith Alcorn / 17 November 2015 Around one in six people with hepatitis C in four US states had their prescriptions for direct-acting antivirals refused by insurers, and almost half of Medicaid recipients were denied reimbursement in 2014 ... Peer workers improve drug users’ engagement with HIV care in Ukraine Roger Pebody / 22 October 2015 An innovative programme in which peer outreach workers use a case management approach to help HIV-positive people who inject drugs to engage with medical services and to begin antiretroviral therapy appears to ... Cost of comprehensive global viral hepatitis prevention and treatment effort might peak at $11 billion in 2025 Keith Alcorn / 15 September 2015 Reaching the World Health Organization’s proposed targets for viral hepatitis control by 2030 could require global funding of $11 billion per year by 2025, Stefan Wiktor of the WHO Hepatitis Programme told ... Medicines Patent Pool looks at hepatitis C Keith Alcorn / 14 September 2015 Greg Perry, Executive Director of the Medicines Patent Pool, told delegates at the World Hepatitis Summit in Glasgow last week that the organisation was considering how it could act to speed up ... WHO recommends global use of newest hepatitis C drugs, urges price reductions Keith Alcorn / 09 April 2014 The World Health Organization has issued global treatment guidelines for hepatitis C, strongly recommending the use of the new direct-acting antivirals sofosbuvir (Sovaldi) with ribavirin for genotypes 1, 2, 3 and 4 or ... Hepatitis C treatment costs could fall to $200 per treatment course for much of the world after 2025 Keith Alcorn / 12 July 2013 Within 15 years, it may be possible to cure hepatitis C for $100-200 for a 12-week treatment course using two direct-acting antivirals plus ribavirin produced by generic manufacturers, according to an analysis ... ← Prev12345Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Access to medicines & diagnostics Hepatitis C elimination Models of care Finance, funding & health economics National policy European policy International policy Activism and civil society Pharmaceutical industry Social issues Conference news Email bulletin archive